Optimizing G6PD testing for Plasmodium vivax case management and beyond: why sex, counseling, and community engagement matter
The DOI matches its Crossref record.
Abstract
Safe access to the most effective treatment options for Plasmodium vivax malaria are limited by the absence of accurate point-of-care testing to detect glucose-6-phosphate dehydrogenase (G6PD) deficiency, the most common human genetic disorder. G6PD-deficient patients are at risk of life-threatening hemolysis when exposed to 8-aminoquinolines, the only class of drugs efficacious against P. vivax hypnozoites. Until recently, only qualitative tests were available in most settings. These can identify patients with severe G6PD deficiency (mostly male) but not patients with intermediate G6PD deficiency (always female). This has led to and reinforced a gap in awareness in clinical practice of the risks and implications of G6PD deficiency in females—who, unlike males, can have a heterozygous genotype for G6PD. Increasing recognition of the need for radical cure of P. vivax, first for patients’ health and then for malaria elimination, is driving the development of new point-of-care tests for G6PD deficiency and their accessibility to populations in low-resource settings. The availability of user-friendly, affordable, and accurate quantitative point-of-care diagnostics for the precise classification of the three G6PD phenotypes can reduce sex-linked disparities by ensuring safe and effective malaria treatment, providing opportunities to develop supportive counseling to enhance understanding of genetic test results, and improving the detection of all G6PD deficiency phenotypes in newborns and their family members.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varied national drug regulators have registered tafenoquine as a single-dose alternative to the standard 14 days daily dosing with primaquine for presumptive anti-relapse therapy (PART) following a diagnosis of P. vivax malaria [32,33].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 72
- R Howes, 2013, G6PD deficiency: global distribution, genetic variants and primaquine therapy., Adv Parasitol., 81, 133-201, 10.1016/B978-0-12-407826-0.00004-7 · DOI · Paper page
- L Luzzatto, 2016, Glucose-6-Phosphate Dehydrogenase Deficiency., Hematol Oncol Clin North Am., 30, 373-93, 10.1016/j.hoc.2015.11.006 · DOI · Paper page
- R Howes, 2012, G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map., PLoS Med., 9, e1001339, 10.1371/journal.pmed.1001339 · DOI · Paper page
- R Howes, 2016, Global Epidemiology of Plasmodium vivax., Am J Trop Med Hyg., 95, 15-34, 10.4269/ajtmh.16-0141 · DOI · Paper page
- L Robinson, 2015, Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model., PLoS Med., 12, e1001891, 10.1371/journal.pmed.1001891 · DOI · Paper page
- C Chu, 2017, Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens., PLoS Med., 14, e1002224, 10.1371/journal.pmed.1002224 · DOI · Paper page
- C Chu, 2019, Tafenoquine and G6PD: a primer for clinicians., J Travel Med., 26, 10.1093/jtm/taz023 · DOI
- M Lacerda, 2019, Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria., N Engl J Med., 380, 215-228, 10.1056/NEJMoa1710775 · DOI · Paper page
- A Llanos-Cuentas, 2019, Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria., N Engl J Med., 380, 229-241, 10.1056/NEJMoa1802537 · DOI · Paper page
- R Rueangweerayut, 2017, Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers., Am J Trop Med Hyg., 97, 702-711, 10.4269/ajtmh.16-0779 · DOI · Paper page
- L Luzzatto, 2015, G6PD deficiency: a polymorphism balanced by heterozygote advantage against malaria., Lancet Haematol., 2, e400-1, 10.1016/S2352-3026(15)00191-X · DOI
- G Domingo, 2019, Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities., Int Health., 11, 7-14, 10.1093/inthealth/ihy060 · DOI · Paper page
- G Domingo, 2013, G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests., Malar J., 12, 10.1186/1475-2875-12-391 · DOI · Paper page
- L von Seidlein, 2013, Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report., Malar J., 12, 10.1186/1475-2875-12-112 · DOI · Paper page
- C Chu, 2018, Primaquine-induced haemolysis in females heterozygous for G6PD deficiency., Malar J., 17, 10.1186/s12936-018-2248-y · DOI · Paper page
- W Taylor, 2019, Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial., Lancet., 394, 929-938, 10.1016/S0140-6736(19)31285-1 · DOI · Paper page
- 2019, Sex and gender in health research: updating policy to reflect evidence., Med J Aust., 10.5694/mja2.50426 · DOI
- J Crow, 1999, Hardy, Weinberg and language impediments., Genetics., 152, 821-5, 10.1093/genetics/152.3.821 · DOI
- G Bancone, 2017, Prevalences of inherited red blood cell disorders in pregnant women of different ethnicities living along the Thailand-Myanmar border [version 2; peer review: 2 approved]., Wellcome Open Res., 2, 72, 10.12688/wellcomeopenres.12338.2 · DOI · Paper page
- L van den Broek, 2016, Glucose-6-phosphate dehydrogenase deficiency: not exclusively in males., Clin Case Rep., 4, 1135-1137, 10.1002/ccr3.714 · doi:10.1002/ccr3.714
- A Anderle, 2018, Point-of-Care Testing for G6PD Deficiency: Opportunities for Screening., Int J Neonatal Screen., 4, 34, 10.3390/ijns4040034 · DOI
- M Kaplan, 1999, Neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes., Pediatrics., 104, 68-74, 10.1542/peds.104.1.68 · doi:10.1542/peds.104.1.68
- M Kaplan, 2001, Acute hemolysis and severe neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes., J Pediatr., 139, 137-40, 10.1067/mpd.2001.115312 · DOI
- A Riskin, 2012, Glucose-6-phosphate dehydrogenase deficiency and borderline deficiency: association with neonatal hyperbilirubinemia., J Pediatr., 161, 191-6.e1, 10.1016/j.jpeds.2012.02.018 · doi:10.1016/j.jpeds.2012.02.018
- F Wang, 2009, Comparison of detection of glucose-6-phosphate dehydrogenase deficiency using fluorescent spot test, enzyme assay and molecular method for prediction of severe neonatal hyperbilirubinaemia., Singapore Med J., 50, 62-7
- Z Premji, 2009, Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria., PLoS One., 4, e6682, 10.1371/journal.pone.0006682 · DOI
- A Tiono, 2009, Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria., Am J Trop Med Hyg., 81, 969-78, 10.4269/ajtmh.2009.09-0351 · DOI
- A Pamba, 2012, Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone., Blood., 120, 4123-33, 10.1182/blood-2012-03-416032 · DOI · Paper page
- P Todd, 1994, Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy., Clin Exp Dermatol., 19, 217-8, 10.1111/j.1365-2230.1994.tb01168.x · doi:10.1111/j.1365-2230.1994.tb01168.x
- M Relling, 2014, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype., Clin Pharmacol Ther., 96, 169-74, 10.1038/clpt.2014.97 · doi:10.1038/clpt.2014.97
- K Robinson, 2019, Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies., Pharmacogenomics J., 19, 305-314, 10.1038/s41397-018-0043-3 · doi:10.1038/s41397-018-0043-3
- G Bancone, 2017, The G6PD flow-cytometric assay is a reliable tool for diagnosis of G6PD deficiency in women and anaemic subjects., Sci Rep., 7, 9822, 10.1038/s41598-017-10045-2 · DOI
- M Kalnoky, 2018, Cytochemical flow analysis of intracellular G6PD and aggregate analysis of mosaic G6PD expression., Eur J Haematol., 100, 294-303, 10.1111/ejh.13013 · DOI
- A Peters, 2009, Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women., J Histochem Cytochem., 57, 1003-11, 10.1369/jhc.2009.953828 · DOI
- J Recht, 2018, Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries., PLoS Negl Trop Dis., 12, e0006230, 10.1371/journal.pntd.0006230 · DOI · Paper page
- J Brito-Sousa, 2019, Clinical Spectrum of Primaquine-induced Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficiency: A 9-Year Hospitalization-based Study From the Brazilian Amazon., Clin Infect Dis., 69, 1440-1442, 10.1093/cid/ciz122 · DOI · Paper page
- C Chu, 2019, Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria., Clin Infect Dis., 68, 1311-1319, 10.1093/cid/ciy735 · DOI
- R Commons, 2019, The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis., BMC Med., 17, 151, 10.1186/s12916-019-1386-6 · DOI · Paper page
- I Tantular, 2010, Incidence and mutation analysis of glucose-6-phosphate dehydrogenase deficiency in eastern Indonesian populations., Acta Med Okayama., 64, 367-73, 10.18926/AMO/41322 · doi:10.18926/amo/41322
- M Alam, 2018, Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity., PLoS One., 13, e0206331, 10.1371/journal.pone.0206331 · DOI · Paper page
- S Pal, 2019, Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient., Am J Trop Med Hyg., 100, 213-221, 10.4269/ajtmh.18-0612 · DOI · Paper page
- 1989, Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group., Bull World Health Organ., 67, 601-11
- V Bhutani, 2008, Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants >or=35 weeks gestation., Neonatology., 94, 63-7, 10.1159/000113463 · DOI
- A Cunningham, 2016, Glucose-6-Phosphate Dehydrogenase Deficiency and the Need for a Novel Treatment to Prevent Kernicterus., Clin Perinatol., 43, 341-54, 10.1016/j.clp.2016.01.010 · DOI
- M Kaplan, 2010, Glucose-6-phosphate dehydrogenase deficiency and severe neonatal hyperbilirubinemia: a complexity of interactions between genes and environment., Semin Fetal Neonatal Med., 15, 148-56, 10.1016/j.siny.2009.10.007 · DOI
- B Olusanya, 2014, Addressing the burden of neonatal hyperbilirubinaemia in countries with significant glucose-6-phosphate dehydrogenase deficiency., Acta Paediatr., 103, 1102-9, 10.1111/apa.12735 · DOI
- B Olusanya, 2015, Management of late-preterm and term infants with hyperbilirubinaemia in resource-constrained settings., BMC Pediatr., 15, 39, 10.1186/s12887-015-0358-z · DOI
- T Meloni, 1992, Marked decline of favism after neonatal glucose-6-phosphate dehydrogenase screening and health education: the northern Sardinian experience., Acta Haematol., 87, 29-31, 10.1159/000204709 · DOI
- C Fu, 2018, Newborn screening of glucose-6-phosphate dehydrogenase deficiency in Guangxi, China: determination of optimal cutoff value to identify heterozygous female neonates., Sci Rep., 8, 833, 10.1038/s41598-017-17667-6 · DOI
- M Abacan, 2019, The Global State of the Genetic Counseling Profession., Eur J Hum Genet., 27, 183-197, 10.1038/s41431-018-0252-x · DOI · Paper page
- V Marsh, 2013, Consulting communities on feedback of genetic findings in international health research: sharing sickle cell disease and carrier information in coastal Kenya., BMC Med Ethics., 14, 41, 10.1186/1472-6939-14-41 · DOI
- A Zhong, 2018, Ethical, social, and cultural issues related to clinical genetic testing and counseling in low- and middle-income countries: a systematic review., Genet Med., 10.1038/s41436-018-0090-9 · DOI
- K Anie, 2016, Community engagement to inform the development of a sickle cell counselor training and certification program in Ghana., J Community Genet., 7, 195-202, 10.1007/s12687-016-0267-3 · DOI
- K Culhane-Pera, 2017, Leaves imitate trees: Minnesota Hmong concepts of heredity and applications to genomics research., J Community Genet., 8, 23-34, 10.1007/s12687-016-0284-2 · DOI
- K Culhane-Pera, 2017, Engaging Hmong adults in genomic and pharmacogenomic research: Toward reducing health disparities in genomic knowledge using a community-based participatory research approach., J Community Genet., 8, 117-125, 10.1007/s12687-017-0292-x · DOI
- N Green, 2016, Family, Community, and Health System Considerations for Reducing the Burden of Pediatric Sickle Cell Disease in Uganda Through Newborn Screening., Glob Pediatr Health., 3, 2333794x16637767, 10.1177/2333794X16637767 · DOI
- L He, 2014, Developing clinical cancer genetics services in resource-limited countries: the case of retinoblastoma in Kenya., Public Health Genomics., 17, 221-7, 10.1159/000363645 · doi:10.1159/000363645
- A Housten, 2016, Feasibility of a Community-Based Sickle Cell Trait Testing and Counseling Program., J Health Dispar Res Pract., 9
- A Wonkam, 2020, Returning incidental findings in African genomics research., Nat Genet., 52, 17-20, 10.1038/s41588-019-0542-4 · DOI
- V Marsh, 2011, 'All her children are born that way': gendered experiences of stigma in families affected by sickle cell disorder in rural Kenya., Ethn Health., 16, 343-59, 10.1080/13557858.2010.541903 · DOI
- B Ley, 2015, The challenges of introducing routine G6PD testing into radical cure: a workshop report., Malar J., 14, 377, 10.1186/s12936-015-0896-8 · doi:10.1186/s12936-015-0896-8
- A Cao, 2008, Thalassaemia and glucose-6-phosphate dehydrogenase screening in 13- to 14-year-old students of the Sardinian population: preliminary findings., Community Genet., 11, 121-8, 10.1159/000113873 · DOI
- L Hsu, 2016, Community Health Workers as Support for Sickle Cell Care., Am J Prev Med., 51, S87-98, 10.1016/j.amepre.2016.01.016 · DOI
- U Amazigo, 2017, Recognising the role of community-directed treatment and of women in the fight against NTDs., Lancet Glob Health., 5, e569-e570, 10.1016/S2214-109X(17)30171-7 · doi:10.1016/s2214-109x(17)30171-7
- Y Tchounkeu, 2012, Changes in stigma and discrimination of onchocerciasis in Africa., Trans R Soc Trop Med Hyg., 106, 340-347, 10.1016/j.trstmh.2012.02.009 · DOI
- Y Dieye, 2017, Feasibility of utilizing the SD BIOLINE Onchocerciasis IgG4 rapid test in onchocerciasis surveillance in Senegal., PLoS Negl Trop Dis., 11, e0005884, 10.1371/journal.pntd.0005884 · DOI
- C Chu, 2019, The impact of using primaquine without prior G6PD testing: a case series describing the obstacles to the medical management of haemolysis., Wellcome Open Res., 4, 25, 10.12688/wellcomeopenres.15100.2 · doi:10.12688/wellcomeopenres.15100.2 · Paper page
- N Ho, 1991, Neonatal jaundice. A second 4-year experience in Toa Payoh Hospital (1986-1989)., J Singapore Paediatr Soc., 33, 149-55
- V Shah, 2007, Identifying risk of neonatal hyperbilirubinaemia and early discharge for glucose-6-phosphate dehydrogenase deficient newborns in Singapore., Ann Acad Med Singapore., 36, 1003-9, 10.47102/annals-acadmedsg.V36N12p1003 · doi:10.47102/annals-acadmedsg.v36n12p1003
- A Devine, 2017, Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis., PLoS Negl Trop Dis., 11, e0005602, 10.1371/journal.pntd.0005602 · DOI
- H Peixoto, 2016, Cost-effectiveness analysis of rapid diagnostic tests for G6PD deficiency in patients with Plasmodium vivax malaria in the Brazilian Amazon., Malar J., 15, 82, 10.1186/s12936-016-1140-x · doi:10.1186/s12936-016-1140-x
- J Xu, 2015, G6PD Deficiency in an HIV Clinic Setting in the Dominican Republic., Am J Trop Med Hyg., 93, 722-9, 10.4269/ajtmh.14-0295 · DOI
Cited by
Satyagraha, A. W., Sadhewa, A., Panggalo, L. V., Subekti, D., Elyazar, I., Soebianto, S., Mahpud, N., Harahap, A. R., & Baird, J. K. (2021) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0009610 · Cited by 12
Metadata
- Authors
- Chu, C. S., Bancone, G., Kelley, M., Advani, N., Domingo, G. J., Cutiongo-de la Paz, E. M., van der Merwe, N., Cohen, J., & Gerth-Guyette, E.
- Venue
- Wellcome Open Research
- Publisher
- F1000 Research Ltd
- Published
- 2020-08-25
- Volume
- 5
- Pages
- 21
- ISSN
- 2398-502X
- Cited by
- 5
- References
- 0
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0/ (tdm)
- Funders
- Department for International Development, UK Government (204139)
- Wellcome Trust (A150007, 096527, 200344)
- Bill & Melinda Gates Foundation (OPP1107113)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimizing G6PD testing for Plasmodium vivax case management and beyond: why sex, counseling, and community engagement matter. https://app.cochat.ai/papers/10.12688/wellcomeopenres.15700.2
- The paper
- Chu, C. S., Bancone, G., Kelley, M., Advani, N., Domingo, G. J., Cutiongo-de la Paz, E. M., van der Merwe, N., Cohen, J., & Gerth-Guyette, E. (2020). Optimizing G6PD testing for Plasmodium vivax case management and beyond: why sex, counseling, and community engagement matter. Wellcome Open Research. https://doi.org/10.12688/wellcomeopenres.15700.2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.